A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Trial Profile

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms ATTAIN
  • Sponsors Biogen
  • Most Recent Events

    • 28 Apr 2017 Results comparing the efficacy of subcutaneous (SC) peginterferon beta-1a and oral teriflunomide in patients from four randomised trials (ADVANCE, ATTAIN, TEMSO and TOWER), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 17 Sep 2016 Results from ADVANCE and ATTAIN studies assessing No Evidence of Disease Activity (NEDA) over 4 years, presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 08 Sep 2016 According to Biogen media release, data from ADVANCE and ATTAIN Studies will be presented at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top